135 related articles for article (PubMed ID: 11350889)
1. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
Yoo GH; Hung MC; Lopez-Berestein G; LaFollette S; Ensley JF; Carey M; Batson E; Reynolds TC; Murray JL
Clin Cancer Res; 2001 May; 7(5):1237-45. PubMed ID: 11350889
[TBL] [Abstract][Full Text] [Related]
2. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma.
Villaret D; Glisson B; Kenady D; Hanna E; Carey M; Gleich L; Yoo GH; Futran N; Hung MC; Anklesaria P; Heald AE
Head Neck; 2002 Jul; 24(7):661-9. PubMed ID: 12112540
[TBL] [Abstract][Full Text] [Related]
4. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
[TBL] [Abstract][Full Text] [Related]
5. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
8. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
9. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model.
Xing X; Zhang S; Chang JY; Tucker SD; Chen H; Huang L; Hung MC
Gene Ther; 1998 Nov; 5(11):1538-44. PubMed ID: 9930307
[TBL] [Abstract][Full Text] [Related]
10. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
11. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
12. [Effect of E1A gene on in vitro growth inhibition and radiochemosensitivity of lymph node metastasis cells of human head and neck squamous cell carcinoma].
Wang XL; Qian XL; Zhao QZ; Xu ZG; Tang PZ
Ai Zheng; 2003 Nov; 22(11):1140-6. PubMed ID: 14613640
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
14. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
15. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery.
Ueno NT; Xia W; Tucker SD; Zhang S; Lopez-Berestein G; Huang L; Hung MC
Oncol Rep; 1999; 6(2):257-62. PubMed ID: 10022986
[TBL] [Abstract][Full Text] [Related]
16. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for head and neck cancer.
Gleich LL
Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
Khorana AA; Rosenblatt JD; Sahasrabudhe DM; Evans T; Ladrigan M; Marquis D; Rosell K; Whiteside T; Phillippe S; Acres B; Slos P; Squiban P; Ross M; Kendra K
Cancer Gene Ther; 2003 Apr; 10(4):251-9. PubMed ID: 12679797
[TBL] [Abstract][Full Text] [Related]
20. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
